To our knowledge, this is the first retrospective study examining the impact of initial therapy of two first generation EGFR-TKIs on the prevention and control of CNS progression in EGFR–mutant NSCLC patients, which could provide an important basis for standardized management of EGFR-TKI therapy for CNS progression of NSCLC with EGFR-sensitizing mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.